NASDAQ:CELU Celularity (CELU) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free CELU Stock Alerts $5.23 +0.29 (+5.87%) (As of 05:21 PM ET) Add Compare Share Share Today's Range$4.90▼$5.2450-Day Range$2.81▼$6.9652-Week Range$1.59▼$8.90Volume48,222 shsAverage Volume275,699 shsMarket Capitalization$101.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Celularity alerts: Email Address Celularity MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 3 Articles This WeekInsider TradingAcquiring Shares$5.35 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.87 out of 5 starsMedical Sector722nd out of 938 stocksPharmaceutical Preparations Industry331st out of 432 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Celularity. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.68% of the float of Celularity has been sold short.Short Interest Ratio / Days to CoverCelularity has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Celularity has recently decreased by 16.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCelularity does not currently pay a dividend.Dividend GrowthCelularity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELU. Previous Next 2.7 News and Social Media Coverage News SentimentCelularity has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Celularity this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for CELU on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Celularity to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celularity insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,352,745.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.70% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.02% of the stock of Celularity is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioCelularity has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow you can target big results without spending big money!While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades! Click here so I can share the details of my $0.25 Cent Trades About Celularity Stock (NASDAQ:CELU)Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Read More CELU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELU Stock News HeadlinesMarch 26, 2024 | finance.yahoo.comCelularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3LMarch 20, 2024 | finanznachrichten.deCelularity Inc.: Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 20, 2024 | markets.businessinsider.comCelularity Announces Submission Of Request For Orphan Drug Designation For PDA-002March 20, 2024 | globenewswire.comCelularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 16, 2024 | finance.yahoo.comCELU Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comCELU Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comCelularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 14, 2024 | globenewswire.comCelularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 12, 2024 | globenewswire.comCelularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World CongressMarch 8, 2024 | edition.cnn.comCelularity Inc. Class AMarch 7, 2024 | globenewswire.comCelularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental CellsFebruary 24, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Announces 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comStocks to Watch: Intuitive Machines, CelularityFebruary 23, 2024 | markets.businessinsider.comCelularity Announce 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comCelularity to Effect 1-for-10 Reverse Stock SplitFebruary 23, 2024 | globenewswire.comCelularity Announces 1-for-10 Reverse Stock SplitFebruary 22, 2024 | finance.yahoo.comCelularity Inc.'s (NASDAQ:CELU) top owners are public companies with 35% stake, while 35% is held by individual investorsFebruary 14, 2024 | finance.yahoo.comCelularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface DiseaseFebruary 14, 2024 | globenewswire.comCelularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface DiseaseFebruary 6, 2024 | benzinga.comCelularity Stock (NASDAQ:CELU) Dividends: History, Yield and DatesFebruary 1, 2024 | finance.yahoo.comCelularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development PipelineJanuary 25, 2024 | finance.yahoo.comCelularity and Genting Leaders Comments on Closing $21 Million Financing TransactionsJanuary 19, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Releases CEO Letter to ShareholdersJanuary 18, 2024 | marketwatch.comCelularity CEO Says 2023 Revenue to Rise About 23% to 27%January 18, 2024 | finance.yahoo.comCelularity Releases CEO Letter to ShareholdersSee More Headlines Receive CELU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings1/02/2024Today3/28/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CELU CUSIPN/A CIK1752828 Webwww.celularity.com Phone908-768-2170FaxN/AEmployees225Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$14.19 million Net Margins-1,226.72% Pretax Margin-1,226.64% Return on Equity30.79% Return on Assets13.28% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.14 Sales & Book Value Annual Sales$17.98 million Price / Sales5.39 Cash Flow$1.82 per share Price / Cash Flow2.75 Book Value$13.36 per share Price / Book0.37Miscellaneous Outstanding Shares19,380,000Free Float15,367,000Market Cap$96.90 million OptionableOptionable Beta0.24 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Robert Joseph Hariri M.D. (Age 65)Ph.D., Founder, CEO & Chairman Comp: $1.24MMr. David C. Beers C.F.A. (Age 54)Chief Financial Officer Comp: $455.02kMr. John R. Haines (Age 66)Senior EVP, Global Manager & Chief Administrative Officer Comp: $503.56kRamji KrishnanChief Technology OfficerCarlos RamirezSVP of Investor RelationsMr. Kyle Harold Fletcher Esq. (Age 39)Executive VP, General Counsel & Chief Compliance Officer Dr. Stephen A. Brigido D.P.M. (Age 48)President of Degenerative Diseases Dr. Adrian Kilcoyne M.B.A. (Age 53)M.D., M.P.H., Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs Sharmila Koppisetti M.D.Senior Vice President of Clinical Dev. Immunology & Drug SafetyMr. Tim WilkSenior Vice President of Technical OperationsMore ExecutivesKey CompetitorsEton PharmaceuticalsNASDAQ:ETONAssertioNASDAQ:ASRTAnixa BiosciencesNASDAQ:ANIXCartesian TherapeuticsNASDAQ:RNACSpero TherapeuticsNASDAQ:SPROView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 258,253 shares on 3/11/2024Ownership: 19.263%Vanguard Group Inc.Bought 258,253 shares on 2/15/2024Ownership: 1.926%Kok Thay LimBought 2,141,098 shares on 1/12/2024Total: $5.35 M ($2.50/share)Robert J HaririBought 935,758 shares on 10/5/2023Total: $1.50 M ($1.60/share)Robert J HaririBought 906,453 shares on 9/29/2023Total: $1.54 M ($1.70/share)View All Insider TransactionsView All Institutional Transactions CELU Stock Analysis - Frequently Asked Questions How have CELU shares performed in 2024? Celularity's stock was trading at $2.4740 at the beginning of 2024. Since then, CELU stock has increased by 111.4% and is now trading at $5.23. View the best growth stocks for 2024 here. Are investors shorting Celularity? Celularity saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 388,300 shares, a decline of 16.8% from the February 29th total of 466,600 shares. Based on an average trading volume of 269,900 shares, the short-interest ratio is presently 1.4 days. Approximately 3.7% of the shares of the company are sold short. View Celularity's Short Interest. When is Celularity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our CELU earnings forecast. How were Celularity's earnings last quarter? Celularity Inc. (NASDAQ:CELU) issued its quarterly earnings results on Tuesday, January, 2nd. The company reported ($0.60) earnings per share for the quarter. The company earned $3.79 million during the quarter. Celularity had a positive trailing twelve-month return on equity of 30.79% and a negative net margin of 1,226.72%. When did Celularity's stock split? Celularity shares reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Celularity's major shareholders? Celularity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (19.26%) and Vanguard Group Inc. (1.93%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri. View institutional ownership trends. How do I buy shares of Celularity? Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELU) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.